Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Argatroban Monohydrate
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Acquisition
Acquisition of Argatroban Business in Europe
Details : Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.
Brand Name : Arganova
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 17, 2024
Lead Product(s) : Argatroban Monohydrate
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?